News
Merck revealed promising Phase 3 trial results for WINREVAIR, a new treatment aimed at pulmonary arterial hypertension (PAH). The HYPERION study involved about 320 global participants already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback